INTRODUCTION: Adenosine deaminase (ADA) deficiency is an ultrarare inherited purine metabolism disorder characterized by severe combined immunodeficiency. Elapegademase-lvlr is a new pegylated recombinant bovine ADA used in enzyme-replacement therapy (ERT) for ADA deficiency. Therefore, replacement with the new drug may eliminate the infectious risks associated with the currently used bovine intestinal-derived product, pegademase. METHODS: We conducted a multicenter, single-arm, open-label, phase 3, and postmarketing clinical study of elapegademase for patients with ADA deficiency. The following biochemical markers were monitored to determine an appropriate dose of elapegademase: the trough deoxyadenosine nucleotide (dAXP) level ≤0.02 µmol/mL in erythrocytes or whole blood and the trough serum ADA activity ≥1100 U/L (equivalent to plasma levels ≥15 µmol/h/mL) indicated sufficient enzyme activity and detoxification as efficacy endpoints and monitored adverse events during the study as safety endpoints. RESULTS: A total of four patients (aged 0-25 years) were enrolled. One infant patient died of pneumonia caused by cytomegalovirus infection whereas the other three completed the study and have been observed in the study period over 3 years. The infant patient had received elapegademase at 0.4 mg/kg/week until decease and the others received elapegademase at maximum doses of 0.3 mg/kg/week for 164-169 weeks. As a result, all four patients achieved undetectable levels of dAXPs together with sufficient enzyme activity, increased T and B cell numbers, and slightly elevated and maintained IgM and IgA immunoglobulin levels. Serious adverse events occurred in three patients, all of which were assessed as unrelated to elapegademase. CONCLUSIONS: This study showed that elapegademase had comparable safety and efficacy to pegademase as ERT for ADA deficiency by demonstrating stable maintenance of sufficient ADA activity and lowering dAXP to undetectable levels, while no drug-related adverse events were reported (Trial registration: JapicCTI-163204).
Agammaglobulinemia , Severe Combined Immunodeficiency , Infant , Humans , Animals , Cattle , Severe Combined Immunodeficiency/drug therapy , Adenosine Deaminase/therapeutic use , Agammaglobulinemia/drug therapy , Multicenter Studies as Topic
INTRODUCTION: Severe Combined Immunodeficiency (SCID) is a primary immunodeficiency disorder characterized by absent or dysfunctional T lymphocytes, leading to defective cellular and humoral immunity requiring urgent hematopoietic stem cell transplantation (HSCT). We report a case of SCID with disseminated Bacille Calmette-Guérin (BCG) infection who developed cytokine release syndrome (CRS) and possible Immune reconstitution inflammatory syndrome (IRIS) after Haploidentical HSCT with post-transplant cyclophosphamide. METHODS: Data were retrospectively retrieved from electronic medical records. RESULT: A 5-month-old male infant was referred with fever, cough, and generalized maculopapular rash for 15 days, and had pallor without hepatosplenomegaly or lymphadenopathy. He had a history of previous male sibling death at 6 months of age due to pneumonia. Investigations: hemoglobin: 4.7 g/dL, TLC-6.37×103/uL, absolute lymphocytes: 0.98×103/uL, platelets: 319×103/uL, bilateral patchy opacities in both lung fields, and low immunoglobulin levels. Lymphocyte subset analysis revealed T-, B+, NK- SCID. Genetic analysis showed a hemizygous mutation in IL2RG (c.314A>G). The child received intravenous (IV) antibiotics, antifungal, antitubercular drugs, irradiated blood products, and IV immunoglobulins. Urgent haploidentical HSCT from the mother was planned. Conditioning was Fludarabine-40 mg/m2/d for 4 days, cyclophosphamide: 14.5 mg/kg/d for 2 days. He received peripheral blood hematopoietic stem cells with CD34- 15×106 cells/kg and CD3- 805×106 cells/kg. Within 2 hours of stem cell infusion, he developed respiratory distress, fever, shock, and flaring of rash. Methylprednisolone was started in view of CRS. On day+2, he had sudden desaturation and bradycardia needing mechanical ventilation and inotropes. His inflammatory markers were elevated (Ferritin: 3640 ng/mL, IL-6:5000 pg/mL, CRP:255 mg/L). In view of high-grade CRS, he received an injection of tocilizumab 8 mg/kg on day +2 and day +4. He received post-transplant cyclophosphamide 5 mg/kg on day +3. The endotracheal secretion GeneXpert was positive for Mycobacterium supporting the diagnosis of disseminated tuberculosis. Our patient had disseminated BCG infection which could also be contributory in the initiation of IRIS as the mother was immunized with the BCG vaccine in childhood so she must be having cytotoxic T cells specific for BCG, which were transferred to the infant with peripheral blood stem cell product. He succumbed to severe acute respiratory distress syndrome and multiorgan dysfunction on day +5 post-transplant. CONCLUSIONS: In haploidentical HSCT of SCID, post-transplant course can be complicated by CRS and IRIS as these patients are inefficient in mounting any response to infused donor lymphocytes resulting in their unregulated growth.
Exanthema , Hematopoietic Stem Cell Transplantation , Severe Combined Immunodeficiency , Humans , Infant , Male , Cyclophosphamide/adverse effects , Cytokine Release Syndrome/complications , Cytokine Release Syndrome/drug therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Retrospective Studies , Severe Combined Immunodeficiency/drug therapy
BACKGROUND: Herpes simplex virus 1 can cause severe infections in individuals who are immunocompromised. In these patients, emergence of drug resistance mutations causes difficulties in infection management. METHODS: Seventeen herpes simplex virus 1 isolates were obtained from orofacial/anogenital lesions in a patient with leaky severe combined immunodeficiency over 7 years, before and after stem cell transplantation. Spatial/temporal evolution of drug resistance was characterized genotypically-with Sanger and next-generation sequencing of viral thymidine kinase (TK) and DNA polymerase (DP)-and phenotypically. CRISPR/Cas9 was used to introduce the novel DP Q727R mutation, and dual infection-competition assays were performed to assess viral fitness. RESULTS: Isolates had identical genetic backgrounds, suggesting that orofacial/anogenital infections derived from the same virus lineage. Eleven isolates proved heterogeneous TK virus populations by next-generation sequencing, undetectable by Sanger sequencing. Thirteen isolates were acyclovir resistant due to TK mutations, and the Q727R isolate additionally exhibited foscarnet/adefovir resistance. Recombinant Q727R mutant virus showed multidrug resistance and increased fitness under antiviral pressure. CONCLUSIONS: Long-term follow-up of a patient with severe combined immunodeficiency revealed virus evolution and frequent reactivation of wild-type and TK mutant strains, mostly as heterogeneous populations. The DP Q727R resistance phenotype was confirmed with CRISPR/Cas9, a useful tool to validate novel drug resistance mutations.
Herpes Simplex , Herpesvirus 1, Human , Immunologic Deficiency Syndromes , Severe Combined Immunodeficiency , Humans , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Herpes Simplex/drug therapy , Severe Combined Immunodeficiency/drug therapy , Gene Editing , Drug Resistance, Viral/genetics , Acyclovir/pharmacology , Acyclovir/therapeutic use , Mutation , DNA-Directed DNA Polymerase/genetics , Drug Resistance, Multiple , Thymidine Kinase/genetics , Thymidine Kinase/therapeutic use
Chandipura virus (CHPV) is a negative-sense single-stranded RNA virus known to cause fatal encephalitis outbreaks in the Indian subcontinent. The virus displays tropism towards the pediatric population and holds significant public health concerns. Currently, there is no specific, effective therapy for CHPV encephalitis. In this study, we evaluated a novel C.B-17 severe combined immunodeficiency (SCID) mouse model which can be used for pre-clinical antiviral evaluation. Inoculation of CHPV developed a lethal infection in our model. Plaque assay and immunohistochemistry detected increased viral loads and antigens in various organs, including the brain, spinal cord, adrenal glands, and whole blood. We further conducted a proof-of-concept evaluation of favipiravir in the SCID mouse model. Favipiravir treatment improved survival with pre-symptomatic (days 5-14) and post-symptomatic (days 9-18) treatment. Reduced viral loads were observed in whole blood, kidney/adrenal gland, and brain tissue with favipiravir treatment. The findings in this study demonstrate the utility of SCID mouse for in vivo drug efficacy evaluation and the potential efficacy of favipiravir against CHPV infection.
Encephalitis , Severe Combined Immunodeficiency , Child , Humans , Animals , Mice , Antiviral Agents/therapeutic use , Drug Evaluation , Mice, SCID , Severe Combined Immunodeficiency/drug therapy , Vesiculovirus/genetics
Deficiency of adenosine deaminase (ADA, EC3.5.4.4), a housekeeping enzyme intrinsic to the purine salvage pathway, leads to severe combined immunodeficiency (SCID) both in humans and mice. Lack of ADA results in the intracellular accumulation of toxic metabolites which have effects on T cell development and function. While untreated ADA-SCID is a fatal disorder, there are different therapeutic options available to restore ADA activity and reconstitute a functioning immune system, including enzyme replacement therapy (ERT). Administration of ERT in the form of pegylated bovine ADA (PEG-ADA) has proved a life-saving though non-curative treatment for ADA-SCID patients. However, in many patients treated with PEG-ADA, there is suboptimal immune recovery with low T and B cell numbers. Here, we show reduced thymus cellularity in ADA-SCID mice despite weekly PEG-ADA treatment. This was associated with lack of effective adenosine (Ado) detoxification in the thymus. We also show that thymocyte development in ADA-deficient thymi is arrested at the DN3-to-DN4 stage transition with thymocytes undergoing dATP-induced apoptosis rather than defective TCRß rearrangement or ß-selection. Our studies demonstrate at a detailed level that exogenous once-a-week enzyme replacement does not fully correct intra-thymic metabolic or immunological abnormalities associated with ADA deficiency.
Adenosine Deaminase/therapeutic use , Agammaglobulinemia/drug therapy , Severe Combined Immunodeficiency/drug therapy , Thymocytes/pathology , Adenosine Deaminase/deficiency , Agammaglobulinemia/pathology , Animals , Cattle , Enzyme Replacement Therapy , Mice, SCID , Severe Combined Immunodeficiency/pathology , Thymocytes/drug effects , Thymocytes/metabolism
Agammaglobulinemia/complications , Hematoma , Kidney Diseases , Severe Combined Immunodeficiency/complications , Adenosine Deaminase/genetics , Adolescent , Agammaglobulinemia/diagnostic imaging , Agammaglobulinemia/drug therapy , Agammaglobulinemia/immunology , B-Lymphocytes/immunology , Glucocorticoids/therapeutic use , Hematoma/diagnostic imaging , Hematoma/drug therapy , Hematoma/etiology , Hematoma/immunology , Humans , Intercellular Signaling Peptides and Proteins/genetics , Kidney/diagnostic imaging , Kidney Diseases/diagnostic imaging , Kidney Diseases/drug therapy , Kidney Diseases/etiology , Kidney Diseases/immunology , Male , Prednisolone/therapeutic use , Severe Combined Immunodeficiency/diagnostic imaging , Severe Combined Immunodeficiency/drug therapy , Severe Combined Immunodeficiency/immunology , Syndrome
Hepatitis E , Severe Combined Immunodeficiency , Adult , Antibodies, Viral/blood , Antiviral Agents/therapeutic use , Chronic Disease , Female , Hepatitis E/drug therapy , Hepatitis E/genetics , Hepatitis E/immunology , Hepatitis E/virology , Hepatitis E virus/genetics , Hepatitis E virus/immunology , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Janus Kinase 3/genetics , RNA, Viral/blood , Recurrence , Ribavirin/therapeutic use , Severe Combined Immunodeficiency/drug therapy , Severe Combined Immunodeficiency/genetics , Severe Combined Immunodeficiency/immunology , Severe Combined Immunodeficiency/virology , T-Lymphocytes/immunology
Adenosine Deaminase/genetics , Agammaglobulinemia/genetics , Anemia, Hemolytic, Autoimmune/genetics , Intercellular Signaling Peptides and Proteins/genetics , Severe Combined Immunodeficiency/genetics , Thrombocytopenia/genetics , Agammaglobulinemia/complications , Agammaglobulinemia/drug therapy , Anemia, Hemolytic, Autoimmune/complications , Anemia, Hemolytic, Autoimmune/drug therapy , Antirheumatic Agents/therapeutic use , Child , Etanercept/therapeutic use , Female , Glucocorticoids/therapeutic use , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Mutation, Missense , Pedigree , Sequence Deletion , Severe Combined Immunodeficiency/complications , Severe Combined Immunodeficiency/drug therapy , Thrombocytopenia/complications , Thrombocytopenia/drug therapy
The deficiency of adenosine deaminase 2 (DADA2) has recently been defined as a monogenetic autosomal recessive autoinflammatory disease. DADA2 is mainly characterized by high fever, livedo racemose, early-onset stroke, mild immunodeficiency and clinically polyarteritis nodosa (PAN)-like symptoms. Mutations in CECR1 (cat eye syndrome chromosome region, candidate 1) are responsible for DADA2. Livedoid racemose, lacunar infarct due to involvement in small vessel of the central nervous system, peripheral neuropathy, digital ulcers and loss of fingers are predominantly seen in the disease which could progress to end-stage organ failure and death in some patients. A wide spectrum of severity in phenotype as well as in the age of onset has been reported in the literature. This phenotypic variability is also found in our clinical practice even in patients with the same mutation. Here, we present a family diagnosed with DADA2, with the previously reported p.Gly47Arg mutation in CECR1.
Agammaglobulinemia/diagnosis , Polyarteritis Nodosa/etiology , Severe Combined Immunodeficiency/diagnosis , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Agammaglobulinemia/complications , Agammaglobulinemia/drug therapy , Age of Onset , Child , Child, Preschool , Family , Female , Genetic Predisposition to Disease , Humans , Immunosuppressive Agents/therapeutic use , Male , Pedigree , Severe Combined Immunodeficiency/complications , Severe Combined Immunodeficiency/drug therapy
Adenosine Deaminase/deficiency , Agammaglobulinemia/drug therapy , Cyclosporine/therapeutic use , Etanercept/therapeutic use , Immunosuppressive Agents/therapeutic use , Severe Combined Immunodeficiency/drug therapy , Tumor Necrosis Factor Inhibitors/therapeutic use , Adenosine Deaminase/genetics , Adolescent , Agammaglobulinemia/genetics , Female , Humans , Intercellular Signaling Peptides and Proteins/genetics , Severe Combined Immunodeficiency/genetics , Treatment Outcome
OBJECTIVE: Deficiency of adenosine deaminase 2 (DADA2) is a potentially fatal monogenic syndrome characterized by variable manifestations of systemic vasculitis, bone marrow failure, and immunodeficiency. Most cases are diagnosed by pediatric care providers, given the typical early age of disease onset. This study was undertaken to describe the clinical phenotypes and treatment response both in adults and in children with DADA2 in India. METHODS: A retrospective analysis of pediatric and adult patients with DADA2 diagnosed at various rheumatology centers across India was conducted. Clinical characteristics, diagnostic findings, and treatment responses were analyzed in all subjects. RESULTS: In total, 33 cases of DADA2 were confirmed in this cohort between April 2017 and March 2020. Unlike previous studies, nearly one-half of the confirmed cases presented during adulthood. All symptomatic patients exhibited features of vasculitis, whereas constitutional symptoms and anemia were more common in pediatric patients. Cutaneous and neurologic involvement were common, and 18 subjects had experienced at least one stroke. In addition, the clinical spectrum of DADA2 was expanded by recognition of novel features in these patients, including pancreatic infarction, focal myocarditis, and diffuse alveolar hemorrhage. Treatment with tumor necrosis factor inhibitors (TNFi) was initiated in 25 patients. All of the identified disease manifestations showed marked improvement after initiation of TNFi, and disease remission was achieved in 19 patients. Two cases were complicated by tuberculosis infection, and 2 deaths were reported. CONCLUSION: This report presents the first case series of patients with DADA2 from India, diagnosed by adult and pediatric care providers. The findings raise awareness of this syndrome, particularly with regard to its presentation in adults.
Agammaglobulinemia/physiopathology , Gastrointestinal Diseases/physiopathology , Hematologic Diseases/physiopathology , Kidney Diseases/physiopathology , Nervous System Diseases/physiopathology , Severe Combined Immunodeficiency/physiopathology , Adenosine Deaminase/genetics , Adenosine Deaminase/metabolism , Adolescent , Adult , Agammaglobulinemia/diagnosis , Agammaglobulinemia/drug therapy , Agammaglobulinemia/genetics , Age of Onset , Anemia/physiopathology , Child , Child, Preschool , Delayed Diagnosis , Female , Glucocorticoids/therapeutic use , Hemorrhage/physiopathology , Humans , India , Infant , Infarction/physiopathology , Intercellular Signaling Peptides and Proteins/genetics , Intercellular Signaling Peptides and Proteins/metabolism , Leukopenia/physiopathology , Lung Diseases/physiopathology , Male , Myocarditis/physiopathology , Pancreatic Diseases/physiopathology , Retrospective Studies , Severe Combined Immunodeficiency/diagnosis , Severe Combined Immunodeficiency/drug therapy , Severe Combined Immunodeficiency/genetics , Stroke/physiopathology , Treatment Outcome , Tumor Necrosis Factor Inhibitors/therapeutic use , Vasculitis/physiopathology , Young Adult
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Herpesvirus 6, Human/isolation & purification , Lymphohistiocytosis, Hemophagocytic/pathology , Osteopetrosis/pathology , Roseolovirus Infections/pathology , Severe Combined Immunodeficiency/pathology , Humans , Infant, Newborn , Lymphohistiocytosis, Hemophagocytic/complications , Lymphohistiocytosis, Hemophagocytic/drug therapy , Male , Osteopetrosis/complications , Osteopetrosis/drug therapy , Prognosis , Roseolovirus Infections/complications , Roseolovirus Infections/drug therapy , Severe Combined Immunodeficiency/complications , Severe Combined Immunodeficiency/drug therapy
Emapalumab, a fully human anti-IFNγ monoclonal antibody, has been approved in the US as second-line treatment of primary hemophagocytic lymphohistiocytosis (HLH) patients and has shown promise in patients with graft failure (GF) requiring a second allogeneic hematopoietic stem cell transplantation (HSCT). The blockade of IFNγ activity may increase the risk of severe infections, including fatal mycobacteriosis. We report a case of secondary HLH-related GF in the context of HLA-haploidentical HSCT successfully treated with emapalumab in the presence of concomitant life-threatening infections, including disseminated tuberculosis (TB). A 4 years old girl with Adenosine Deaminase-Severe Combined Immunodeficiency complicated by disseminated TB came to our attention for ex-vivo hematopoietic stem cell-gene therapy. After engraftment failure of gene corrected cells, she received two HLA-haploidentical T-cell depleted HSCT from the father, both failed due to GF related to concomitant multiple infections and secondary HLH. Emapalumab administration allowed to control HLH, as well as to prevent GF after a third haplo-HSCT from the mother. Remarkably, all infections improved with antimicrobial medications and disseminated TB did not show any reactivation. This seminal case supports emapalumab use for treatment of secondary HLH and prevention of GF in patients undergoing haplo-HSCT even in the presence of multiple infections, including TB.
Hematopoietic Stem Cell Transplantation , Lymphohistiocytosis, Hemophagocytic , Severe Combined Immunodeficiency , Tuberculosis , Adenosine Deaminase , Agammaglobulinemia , Antibodies, Monoclonal/therapeutic use , Antibodies, Neutralizing , BCG Vaccine , Child, Preschool , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Lymphohistiocytosis, Hemophagocytic/drug therapy , Lymphohistiocytosis, Hemophagocytic/etiology , Severe Combined Immunodeficiency/complications , Severe Combined Immunodeficiency/drug therapy , Tuberculosis/complications , Tuberculosis/drug therapy
Adenosine Deaminase/deficiency , Agammaglobulinemia/genetics , Biological Factors/therapeutic use , Glucocorticoids/therapeutic use , Intercellular Signaling Peptides and Proteins/genetics , Severe Combined Immunodeficiency/genetics , Adenosine Deaminase/genetics , Adolescent , Adult , Agammaglobulinemia/drug therapy , Agammaglobulinemia/epidemiology , Child , Female , Genotype , Humans , Incidence , Intercellular Signaling Peptides and Proteins/deficiency , Male , Phenotype , Prognosis , Severe Combined Immunodeficiency/drug therapy , Severe Combined Immunodeficiency/epidemiology , Turkey/epidemiology , Young Adult
INTRODUCTION: Adenosine deaminase (ADA) deficiency causes severe immunodeficiency that is lethal in infancy. Enzyme replacement therapy (ERT) can improve the metabolic, immune and non-immune abnormalities in patients prior to transplantation, however, its benefits over extended periods are not well characterized. We describe a 28-year-old female who received ERT for 27 years. She suffered from EBV negative B cell lymphoma of the hip at 14 years of age and Guillian-Barre Syndrome 2 years later. At 22 years of age, she experienced a gastrointestinal infection with Mycobacterium genavense. At 26 years of age, lymphoma reoccurred with multiple liver lesions followed by Mycobacterium genavense infection with dissemination to the brain. Throughout this period, ADA activity in the plasma was within the therapeutic range. Repeated evaluations demonstrated very low lymphocyte counts and impaired T cell function. CONCLUSIONS: ERT might be insufficient to maintain normal immunity over extended periods in some ADA-deficient patients.
Adenosine Deaminase/deficiency , Agammaglobulinemia/drug therapy , Enzyme Replacement Therapy , Severe Combined Immunodeficiency/drug therapy , Adenosine Deaminase/therapeutic use , Adult , Agammaglobulinemia/epidemiology , Female , Humans , Morbidity , Severe Combined Immunodeficiency/epidemiology
Agammaglobulinemia/chemically induced , B-Lymphocytes/cytology , Carbamazepine/adverse effects , Drug Hypersensitivity/pathology , Sodium Channel Blockers/adverse effects , Adult , Carbamazepine/therapeutic use , Female , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Immunoglobulin M/blood , Lymphocyte Count , Severe Combined Immunodeficiency/drug therapy , Sodium Channel Blockers/therapeutic use
Adenosine Deaminase/deficiency , Agammaglobulinemia/drug therapy , Enzyme Replacement Therapy/methods , Pregnancy Complications/drug therapy , Severe Combined Immunodeficiency/drug therapy , Adenosine Deaminase/administration & dosage , Adenosine Deaminase/immunology , Adult , Agammaglobulinemia/immunology , Drug Administration Schedule , Female , Humans , Pregnancy , Pregnancy Complications/immunology , Severe Combined Immunodeficiency/immunology , Treatment Outcome